# IPF Partners

> IPF Partners is a VC fund in Luxembourg backing Health Care and Medical. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Luxembourg, Luxembourg
- Total investments: 9
- Last investment: Mar 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ipf-partners/
- Website: http://www.ipfpartners.com

IPF Partners is a alternative financing provider focused on the European healthcare sector. IPF invests directly in emerging, commercial-stage European pharma/biotech, medtech and diagnostics companies.

## Contacts

5 contacts available for IPF Partners. Shizune tracks 2 team members at IPF Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ipf-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series C | $28M–$130M |
| Post-IPO Debt | $3.5M–$30M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Medical | 2 | 22% |
| Biotechnology | 2 | 22% |
| Pharmaceutical | 2 | 22% |
| Hospital | 1 | 11% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 22% |
| Post-IPO Debt | 2 | 22% |
| Series B | 1 | 11% |
| Series D | 1 | 11% |
| Funding Round | 1 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Finland | 2 | 22% |
| France | 1 | 11% |
| Germany | 1 | 11% |
| United States | 1 | 11% |
| United Kingdom | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Edouard Guillet | Partner | 1 | https://shizune.co/investors/profile/edouard-guillet |
| Georges Ralli | Partner | 0 | https://shizune.co/investors/profile/georges-ralli |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Faron Pharmaceuticals | Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. | $3.5M | Post-IPO Debt | Mar 04, 2024 |  |
| Patient 21 | Patient21 believes that the doctor-patient connection is the cornerstone to good healthcare and that it is their responsibility to remove any impediments to it. They think that the greatest healthcare necessitates cross-specialty collaboration and universal data access. Always with one purpose in mind: to help patients and physicians make betterdecisions.In comparison to today's linked world, healthcare appears to be trapped in the past. It continues to use the same analogue and isolated processes. Patient21  is on a quest to usher healthcare into the twenty-first century. They use data to help doctors give the most personalized treatments possible. And, with the help of their professional network, they are attempting to give a comprehensive perspective of their client's health. | $32M | Debt Financing | May 22, 2023 |  |
| Poxel | Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.They believe that targeting cellular energyregulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC). |  | Post-IPO Debt | Aug 08, 2022 |  |
| Faron Pharmaceuticals | Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. | $30M | Post-IPO Debt | Feb 28, 2022 |  |
| Caresyntax | Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $130M | Series C | Sep 16, 2021 |  |
| Lumeon | Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $30M | Series D | Aug 11, 2020 |  |
| Caresyntax | Caresyntax is a digital surgery platform that enables OR teams to predict and improve surgical performance. Its enterprise-grade digital surgery platform delivers insights to improve patient outcomes by using proprietary software and AI to analyze large volumes of video, audio, images, device data, clinical, and operational data in and around theOR.Caresyntax insights help surgeons benchmark and improve their care, hospital administrators use surgical resources more efficiently, medical device companies advance better products, and insurance companies understand risk and devise more tailored policies. The software is used in more than 4,000 operating rooms worldwide, has supported more than 30,000 surgeons, and improved care for more than 2 million patients. | $45.6M | Series B | Dec 12, 2019 |  |
| Lumeon | Lumeon is a digital health company that has defined the market for Care Pathway Management (CPM). From scheduling and revenue management to clinical reporting and aftercare, by looking across the end-to end care pathway, Lumeon addresses the system, and not just the symptom, behind healthcare transformation. Lumeon's customers number amongEurope’s fastest growing and most innovative healthcare providers including BUPA, Nuffield Health, Alliance Medical, HCA, Optegra and Newmedica. It is headquartered in London employing over 90 people. | $28M | Series C | Dec 04, 2018 |  |
| Mendor | Mendor is a Finnish company, committed to the design, development and marketing of advanced diabetes management products. Mendor has launched a revolutionary, discreet, easy to use, portable all-in-one blood glucose meter and web-based software application for the daily management of diabetes. Mendor has designed its products together with usersand diabetes experts to address the needs of people with diabetes requiring regular blood glucose monitoring. | $7.1M |  | Jul 07, 2014 |  |

9 of 9 investments shown.

## Co-investors
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 2 deals together
- [Gilde Healthcare](https://shizune.co/investors/profile/gilde-healthcare-partners) — VC Fund, 2 deals together
- [Intel Capital](https://shizune.co/investors/profile/intel-capital) — VC Fund, 2 deals together
- [LSP BioVentures](https://shizune.co/investors/profile/lsp-bioventures) — VC Fund, 2 deals together
- [MTIP AG](https://shizune.co/investors/profile/medtech-innovation-partners) — VC Fund, 2 deals together
- [Optum Ventures](https://shizune.co/investors/profile/optum-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

### Similar country
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund
- [Lifeline Ventures](https://shizune.co/investors/profile/lifeline-ventures) — VC Fund
- [Tesi](https://shizune.co/investors/profile/tesi) — VC Fund

## Featured in investor lists
- [Wellness Investors in Finland](https://shizune.co/investors/wellness-investors-finland)
- [Wellness VC Funds in Finland](https://shizune.co/investors/wellness-vc-funds-finland)
- [Health Care VC Funds in Finland](https://shizune.co/investors/health-care-vc-funds-finland)
- [Health Care Investors in Finland](https://shizune.co/investors/health-care-investors-finland)

## FAQ

### What does IPF Partners invest in?

IPF Partners invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Post-IPO Debt stage. Most of the 9 investments tracked by Shizune back companies in Finland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is IPF Partners's check size?

IPF Partners typically joins rounds of $28M–$130M at Series C and $3.5M–$30M at Post-IPO Debt. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds IPF Partners participates in.

### How do I contact IPF Partners?

Public channels for IPF Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at IPF Partners?

The team at IPF Partners includes Edouard Guillet (Partner) and Georges Ralli (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co